Abstract N-acetylglucosaminyltransferase V (GnT-V), an enzyme that catalyzes the formation of the N-linked β-1-6 branching of oligosaccharides, is related to the radiosensitivity of nasopharyngeal carcinoma (NPC). Cetuximab (C225) is an epidermal growth factor receptor (EGFR) inhibitor used as a radiosensitizer in the treatment of NPC. In this study, we used GnT-V as a molecular target to further sensitize cetuximab-treated NPC cells to radiation. The results from two NPC cell lines (CNE1 and CNE2) revealed that the silencing of GnT-V enhanced cetuximab-induced radiosensitivity by decreasing the β-1-6 branching of oligosaccharides on the EGFR. GnT-V down-regulation combined with cetuximab decreased the survival fraction, healing rate and cell viability and increased the apoptosis rate. Concomitantly, the combination of cetuximab and irradiation did not change the EGFR mRNA and protein levels and decreased the β-1-6 branching on the EGFR. Subsequently, we further explored the signaling downstream of EGF, particularly the PI3K/Akt signaling pathway, and discovered that treatment consisting of GnT-V down-regulation, irradiation and cetuximab was negatively correlated with phospho-Akt and phspho-PI3K. Finally, an in vivo experiment with radiotherapy revealed that the combination of GnT-V down-regulation and cetuximab decelerated tumor growth. In summary, our study demonstrated that the combination of decreased GnT-V activity and cetuximab enhanced NPC radiosensitivity, and the possible mechanism underlying this effect might involve the N-linked β1-6 branching of the EGFR.
Introduction
Nasopharyngeal carcinoma (NPC) has a high morbidity in certain geographical areas, such as southern Asia, the Mediterranean basin and southern China. According to the statistics issued by the Chinese Cancer Registry Annual Report, the incidence rate of NPC is 3.61 per 100,000 (Jie He 2012). More than 97% of patients have undifferentiated carcinoma (Ayan et al. 2003) , and the major treatment is radiation therapy (Ishigami et al. 2007 ). However, not all patients are sensitive to radiotherapy, and more than 40% of patients show distant metastasis and recurrence (Chan et al. 2011 ).
Therefore, clinicians select a radiosensitizer that can be included in effective therapeutic strategies that yield improved clinical outcomes.
Cetuximab, a monoclonal antibody that binds to EGFR, is regarded as a radiosensitizer in NPC treatment. The addition of cetuximab as a radiosensitizer to first-line radiotherapy improves the median overall survival (OS) and 5-year OS of patients from 29.3 to 49.0 months and from 36.4% to 45.6%, respectively (Bonner et al. 2006) . The epidermal growth factor receptor (EGFR), which belongs to the ErbB family of receptor tyrosine kinases (RTKs), is involved in the pathogenesis and progression of different types of carcinoma (Normanno et al. 2006 ). This receptor is overexpressed in 80-100% of head and neck cancers (Kim et al. 2001) and is blocked by cetuximab. Blockage of the receptor results in its inability to be imported into the nucleus to activate radiation-induced DNA-dependent kinases, and this process inhibits DNA repair and increases the radiosensitivity of the treated cells (Dittmann et al. 2005) . Unfortunately, the cancer in some patients remains insensitive to radiotherapy, even after the administration of cetuximab. Therefore, elucidation of the mechanism of cetuximabmediated radiosensitivity in NPC patients and the selection of patients who may benefit from cetuximab are necessary.
β-1,6-N-acetylglucosaminyltransferase V, encoded by Mgat5, is an enzyme that adds GlcNAc to β-1,6-linked branches (Dennis 2002; Lau and Dennis 2008) . Swainsonine inhibits Golgi α mannosidase II, preventing the formation of β-1,6-linked branches. Emerging lines of evidence suggest that N-acetylglucosaminyltransferase V (GnT-V) and the resulting β-1,6-linked branches are elevated in various cancers, including hepatocellular carcinoma (Wang et al. 2009 ), renal cell carcinoma (Liu et al. 2015) , gastric cancer (Huang, Chen et al. 2014) and breast cancer (Guo et al. 2007) , and contribute to invasion and metastasis. In addition, GnT-V increases the expression of GlcNAc β-1,6 complex-type N-glycans on cell-surface receptors (Guo et al. 2007; Pocheć et al. 2013 ) to affect chemotherapy resistance and radioresistance by activating signal transduction pathways (Wang et al. 2009 ). The EGFR is one of the target molecules affected by GnT-V, and suppression of GnT-V increases the radiosensitivity of small-cell lung cancer (Huang et al. 2015) , prostate cancer (Huang, Chen et al. 2014) and NPC (Wei et al. 2011) , as has been verified in our previous studies.
As mentioned above, glycans related to GnT-V are involved in radiosensitivity in NPC cells. However, the mechanism through which cetuximab acts as a radiosensitizer remains to be explored. The alteration of branched N-glycans on cell-surface receptors results in functional changes, and because cetuximab targets the EGFR, we questioned the existence of an association between glycans and cetuximab. Therefore, we hypothesized that GnT-V likely participates in the cetuximabmediated induction of radiosensitivity by altering the β-1,6-linked branches on the EGFR, which is one of the mechanisms that increases the radiosensitivity of NPC cells. To validate this hypothesis, two NPC cell lines were used in a series of assays, and the results revealed that the silencing of GnT-V enhances the cetuximab-induced radiosensitivity of NPC through glycosylation of the EGFR. These findings indicate that inhibition of β-1,6 branches on the EGFR might be a promising personalized medicine approach for NPC patients.
Results
Lentivirus-mediated shRNA inhibits GnT-V mRNA and protein expression in NPC cell lines
To determine the expression level of GnT-V in CNE1, CNE2 and HNE1 cells, RT-PCR and Western blot analyses were performed. As shown in Figure 1A , CNE2 cells expressed 7.5-fold and 2.30-fold higher levels of GnT-V mRNA and protein than HNE1 cells (Fig. 1A) , and CNE1 cells expressed 1.41-fold and 1.36-fold higher levels of GnT-V mRNA and protein than HNE1. In other words, HNE1 cells expressed the lowest levels of GnT-V among these three NPC cell lines. Because CNE1 and CNE2 presented higher expression of GnT-V, we selected CNE1 and CNE2 for our subsequent lentiviral transfection experiment, which included the development of GnT-V-suppressed cell models, denoted CNE1-1564, CNE1-2224, CNE2-1564 and CNE2-2224. The expression levels of GnT-V mRNA in these cell models were 36.3%, 33.9%, 42% and 35.5% of the levels found in the control groups, respectively ( Figure 1B and C) . Similarly, the GnT-V protein levels in the CNE1-1564, CNE1-2224, CNE2-1564 and CNE2-2224 cell models were decreased by 60.13%, 59.89%, 43.67% and 46.18%, respectively ( Figure 1B and C) . Moreover, negative control groups (CNE1-NC and CNE2-NC) were also established. The mRNA and protein levels did not present any significant differences between the negative control groups and nontransfected cells (P > 0.05).
Cetuximab further sensitizes NPC cells to radiation after GnT-V knockdown
In our experiments, CCK-8 assays were used to determine the halfmaximal inhibitory concentration (IC 50 ) of cetuximab in CNE1 and CNE2 cells. The IC 50 values of CNE1 and CNE2 cells were 717 and 1244 μg/mL, respectively ( Figure 2A) ; thus, values equal to one-fifth of the IC 50 concentrations were selected as the experimental concentrations (Zhang 2012) . Afterward, cetuximab at the above-mentioned concentrations was added to the NPC cells used in our study, and the results demonstrated that these low concentrations of cetuximab hardly affected the cell viability of CNE1 and CNE2 cells ( Figure 2B ).
To assess the radiosensitivity of NPC cells and thus explore the interaction among GnT-V, cetuximab and radiation, we performed colony formation, wound healing, cell proliferation and flow cytometry assays. A 6-Gy radiation dose was selected for the majority of the experiments because our research group previously found that the most significant difference was obtained between 6 and 0 Gy in NPC cells (Zhuo et al. 2012) .
First, colony formation assays were performed with various doses of irradiation (0, 2, 4, 6 and 8 Gy) , and the sensitizing enhancement ratio (SER) was used to evaluate the increased sensitivity of the cells. As shown in Figure 2C , the survival fractions decreased with increasing irradiation in both CNE1 and CNE2 cells. At the same radiation dose, CNE2-NC had the highest survival, as assessed in terms of the survival fractions of each group. CNE2-2224 presented higher survival than CNE2-2224/cetuximab, and CNE2-NC/cetuximab showed decreased survival compared with CNE2-NC ( Figure 2C ). The SER of these cells was found to equal 3.23. For CNE1, the survival fractions of CNE1-NC were higher than those of CNE1-NC/cetuximab and CNE1-1564, and the survival fraction of CNE1-1564 was higher than that of CNE1-1564/cetuximab. Thus, the SER of these cells was 2.42. Therefore, with irradiation, GnT-V down-regulation decreased the clonogenicity of NPC cells, and the level of clonogenicity was further reduced when the treatment was combined with cetuximab.
As shown by the results of the wound healing assays presented in Figure 2D , the mean healing rates of CNE2-1564 and CNE2-2224 cells were lower than that of CNE2-NC. Moreover, the mean healing rates of CNE2-1564/cetuximab and CNE2-2224/cetuximab were lower than those of CNE2-1564 and CNE2-2224. Similarly, after 6-Gy radiation, the healing rate of CNE2-NC/cetuximab was reduced compared with that of CNE2-NC. The outcomes found for CNE1 cells were similar ( Figure 2D) .
All of the different groups of cells were exposed to 6-Gy radiation prior to being subjected to CCK-8 assays, which revealed that the relative cell viability of CNE2-NC exceeded the viabilities of CNE2-1564 and CNE2-2224 and that the numbers of CNE2-1564 and CNE2-2224 cells after exposure to 6-Gy radiation were higher than those of CNE2-1564/cetuximab and CNE2-2224/cetuximab. The viability rate of CNE2-NC was also increased compared with that of CNE2-NC/cetuximab ( Figure 2E ). A parallel result was also discovered for the CNE1 cell line: GnT-V down-regulation combined with cetuximab could further decrease the cellular viability rate compared with the NC group ( Figure 2E ).
The apoptosis rates of the cells subjected to the 6-Gy radiation treatment were measured by flow cytometry. The apoptosis rate of cells with decreased GnT-V expression and treated with cetuximab showed a modest increase compared with those of the cells with downregulated GnT-V expression and of the control cells ( Figure 2F ).
In summary, the combination of GnT-V down-regulation with cetuximab decreased cellular migration and survival and enhanced radiation-induced apoptosis, thereby sensitizing NPC cells to radiotherapy.
Cetuximab with irradiation promotes aberrant β-1,6 branches on the EGFR To confirm that β-1,6-linked branches are involved in NPC cell radiosensitivity, we then used the N-oligosaccharide chain inhibitor swainsonine (sw, 1 μg/mL) to inhibit the β-1,6-linked branches of CNE2 that highly express GnT-V. Clone formation assays performed after exposure to 0, 2, 4, 6 and 8 Gy ranked the cells in the following order based on decreasing survival fractions ( Figure 3A ): CNE2 > CNE2/cetuximab > CNE2/cetuximab/sw. The SER was 1.25. The results of wound healing assays of cells subjected to 6-Gy radiation ranked the cells in the following order based on decreasing migration speed ( Figure 3B ): CNE2 > CNE2/cetuximab > CNE2/ cetuximab/sw. Analogously, CCK-8 assays ranked the NPC cells in the following order based on decreasing relative cell viability ( Figure 3D ): CNE2 > CNE2/cetuximab > CNE2/cetuximab/sw. In contrast, the ranking of the cells based on decreasing apoptosis rate The GnT-V protein and mRNA levels in HNE1, CNE1 and CNE2 were analysed by Western blot and RT-PCR. GAPDH was used as a control. Among these three cell lines, CNE2 showed the highest GnT-V expression level, and HNE1 presented the lowest GnT-V expression level. (B) CNE1 and CNE2 were transfected with GnT-V-shRNA or NC lentivirus and evaluated by western blot and RT-PCR. GAPDH was used as a control. (C) Lentivirus-transfected cells were examined by light and fluorescence microscopy. P values were calculated through one-way ANOVA (*P < 0.05). This figure is available in black and white in print and in color at Glycobiology online.
was CNE2/cetuximab/sw > CNE2/cetuximab > CNE2 ( Figure 3C ). These data indicated that inhibition of β-1,6-linked branches sensitized NPC cells to irradiation, showing that β-1,6-linked branches might influence the radiosensitivity.
To further investigate whether alteration of β-1,6 branches on the EGFR is one of the mechanisms that can affect the radiosensitivity of NPC cells, we first detected the EGFR expression levels in each group by RT-PCR and Western blot assays. As demonstrated in Figure 3E , the EGFR expression levels in the CNE1 and CNE2 groups were invariant. Lectin blots were then performed, and the results showed that the total numbers of β-1,6 branches varied among the groups ( Figure 3F ). CNE2-NC had the highest number of β-1,6-linked branches, whereas CNE2-1564 and CNE2-2224 had more β-1,6-linked branches than CNE2-1564/cetuximab and CNE2-2224/cetuximab. The results obtained for the CNE1 cells were consistent with the above-described outcomes, indicating that increased cellular sensitivity to radiation was negatively related to the number of β-1,6 branches, whereas insensitivity was positively correlated with β-1,6 branches. Moreover, L-PHA precipitation, blotting and probing with anti-EGFR staining were performed, and a significant decrease was observed in the cells that were more responsive to radiotherapy ( Figure 3G ), indicating that cetuximab-treated cells with down-regulated GnT-V expression had lower levels of β-1,6-branched glycans on the EGFR than that cells with down-regulated GnT-V expression. Treatment consisting of cetuximab combined with irradiation promoted aberrant β-1,6 branches on the EGFR. The above-described analysis demonstrated that aberrant β-1,6 branches on the EGFR likely contributed to radiosensitivity related to cetuximab and GnT-V.
Radiotherapy combining GnT-V down-regulation and cetuximab decelerates tumor growth
The efficacy of GnT-V down-regulation in combination with cetuximab on tumor growth was also explored in xenograft nude mice subjected to radiotherapy. Irradiation with 2 Gy was administered on days 1-5, and cetuximab or swainsonine was administered on days 1, 3 and 5. As shown in Figure 3A and B, tumors with down-regulated The IC 50 values of CNE1 and CNE2 were 717 and 1244 μg/mL, respectively. (B) CCK-8 assays were performed to calculate the growth rates of CNE1 and CNE2 cells using cetuximab at a concentration equal to one-fifth of the IC 50 . In addition, CNE1-NC and CNE1-1564 showed no significant difference in their growth rates, and CNE2-NC and CNE2-2224 did not show significantly different growth rates. (C) NPC cells were exposed to various irradiation doses (0, 2, 4, 6 and 8 Gy) and subjected to colony formation assays. Representative images and quantitative analysis of the results of clone formation assays are shown. The SER of CNE1 cells was 2.42, and the SER of CNE2 cells was 3.23. (D) All of the cells from different groups were exposed to 6-Gy radiation. Wound healing assays showed that the combination of cetuximab treatment with GnT-V silencing inhibited cell mobility, and representative images and the results of a quantitative analysis are shown. (E) All cells from the different groups were exposed to 6-Gy radiation, and CCK-8 assays were performed to calculate the growth rates of NPC cells. (F) All of the cells from the different groups were exposed to 6-Gy radiation, and the cell apoptosis rates were evaluated by quantitative flow cytometry analysis. P values were calculated through multiple classification ANOVA (*P < 0.05). This figure is available in black and white in print and in color at Glycobiology online.
Fig. 2. Continued
GnT-V expression and treated with cetuximab showed the slowest growth, whereas the NC group grew much faster than the tumors with down-regulated GnT-V expression and the tumors treated with cetuximab. Similarly, tumors administered both the glycosylation inhibitor swainsonine and cetuximab showed the slowest growth ( Figure 4A -C). The Bcl-2 level in the tumor xenografts was also detected ( Figure 4D ). The cetuximab-treated tumors with downregulated GnT-V expression and the tumors treated with cetuximab and swainsonine presented the lowest Bcl-2 protein level. We also detected the levels of β-1,6 branches in xenograft tumors by immunohistochemistry, and the results were consistent with the in vitro findings ( Figure 4E ). These results suggested that cetuximab combined with GnT-V down-regulation enhanced the response of nasopharyngeal cancer cells to radiation and decelerated tumor growth.
Reduced β-1,6 branches on the EGFR decrease PI3K/AKT signaling Accumulating evidence confirms that PI3K/Akt signaling is overactive in radiotherapy-resistant head and neck squamous cell carcinoma. To further investigate whether changes in the radiosensitivity of CNE1 and CNE2 cells were also related to PI3K/Akt signaling, as was previously confirmed in previous studies, we detected the protein levels of phospho-PI3K and phospho-Akt in our cells. The β-1,6 branches produced by GnT-V belong to N-glycans, and the EGFR is a member of the RTK family. It has been reported that N-linked glycosylation affects RTK signaling and sensitizes tumor cells via Akt (Contessa et al. 2008) . Accordingly, we questioned whether radiation-induced alteration of β-1,6 branches on the EGFR might influence its downstream signaling. Cells were treated with 6-Gy irradiation prior to lysis. A Western blot assay revealed that the total Akt level did not vary among the different groups, but the phospho-Akt and phospho-PI3K levels presented differences ( Figure 5 ): the phospho-Akt and phospho-PI3K levels in CNE2-1564 and CNE2-2224 cells were lower than those in CNE2-NC, and the levels detected in CNE2-1564/cetuximab and CNE2-2224/cetuximab were lower than those found in CNE2-1564 and CNE2-2224. CNE2-NC/cetuximab presented reduced levels of phospho-Akt and phospho-PI3K compared with CNE2-NC. The CNE1 cells presented similar results. In brief, the irradiationinduced alteration of β-1,6 branches on the EGFR might influence PI3K/AKT signaling.
Discussion
Radiotherapy is the primary treatment modality for NPC patients at all locally and regionally confined stages (Everett and Vokes 1997) . Cetuximab is a monoclonal antibody against the EGFR tyrosine kinase and has demonstrated efficacy against squamous cell carcinoma of the head and neck as a single agent and in combination with radiotherapy (Mendelsohn et al. 2015) . However, some patients are insensitive to radiotherapy even after the addition of cetuximab, and the reasons for this insensitivity are unclear. Therefore, elucidation of the mechanism underlying radiation resistance mediated by cetuximab and selection of individuals who can specifically benefit from cetuximab are necessary. GnT-V is an N-glycan glycosyltransferase that catalyzes the β-1,6-GlcNAc branched structure. Many studies have demonstrated that the levels of GnT-V and its enzymatic product, β-1,6-branches, are aberrantly up-regulated in cancer cells that are highly involved in cancer growth and metastasis (Kizuka and Taniguchi 2016; Przybylo et al. 2008; Taniguchi and Kizuka 2015) . Our previous studies revealed that the knockdown of GnT-V in various tumor cell lines enhances their sensitivity to radiation (Zhuo et al. 2012; Huang, Chen et al. 2014; Huang et al. 2015) . In the present study, we discovered that GnT-V-silenced NPC cells were more sensitive to radiation and possessed fewer β-1,6-GlcNAc branches, demonstrating that β-1,6-GlcNAc branches are closely related to radiosensitivity. Alterations of branched N-glycans on cell-surface receptors result in functional changes (Taniguchi and Kizuka 2015) . Because the mechanism underlying the action of cetuximab as a radiosensitizer is not fully understood, we hypothesized that alteration of β-1,6-GlcNAc branches on the EGFR after cetuximab administration is one of the mechanisms contributing to NPC cell radiosensitivity. Through in vitro experiments, we found that GnT-V silencing in combination with cetuximab treatment increased the apoptosis rate and decreased the survival fraction, healing rate and viability of the cells. Furthermore, administration of swainsonine to inhibit β-1,6-linked branches increased the response of the cells to radiotherapy. Additionally, the in vivo experiments involving radiotherapy showed that xenograft tumors grew more Fig. 3 . Alteration of β-1,6-linked branches on the EGFR is related to irradiation and cetuximab. CNE2 cells were treated with swainsonine (1 μg/mL) for 24 h prior to the experiments. (A) The clonogenicities of CNE2 cells subjected to different treatments and various radiation levels (0, 2, 4, 6 and 8 Gy) were assessed by colony formation assays. Representative images of the quantitative analysis results are shown. The SER was 1.25. (B) All cell groups were exposed to 6-Gy irradiation. The wound healing assays revealed that cell mobility was inhibited after formation of β-1,6-linked branches in NPC cells. Representative images and the quantitative analysis results are shown. (C) All cell groups were exposed to 6-Gy irradiation, and CCK-8 assays were performed to measure the cell viabilities of CNE2 cells subjected to different treatments. (D) All cell groups were exposed to 6-Gy irradiation, and flow cytometry was performed to evaluate the apoptosis rates of CNE2 cells subjected to different treatments. The results of a quantitative analysis are shown. (E) All cells from the different groups were exposed to 6-Gy radiation prior to evaluation by Western blot and RT-PCR assays. Indistinct levels of EGFR were found in the different groups. GAPDH was used as a control. (F) All of the cells from the different groups were exposed to 6-Gy radiation prior to lysis. A lectin blot analysis revealed the numbers of β-1,6-linked branches of each group. GAPDH was used as a control. (G) All of the cells from the different groups were exposed to 6-Gy radiation prior to lysis. PHA-L precipitation (blotting and probing with anti-EGFR staining) was performed to quantify the EGFR levels of the different groups. P values were calculated through multiple classification ANOVA (*P < 0.05). This figure is available in black and white in print and in color at Glycobiology online.
slowly than those from the GnT-V-silenced tumors and the cetuximabtreated tumors. In addition, the cells showed increased sensitivity to radiation had fewer β-1,6-linked branches than those resistant to radiation, and their total EGFR level remained unchanged, demonstrating that cetuximab treatment combined with either GnT-V down-regulation or decreased β-1,6-linked branches increases the sensitivity of NPC cells to radiation. In contrast, in normal human fibroblasts, the inhibition of N-linked glycosylation reduced the EGFR protein levels without enhancing the radiosensitivity of the cells (Contessa et al. 2008) . Because NPC cells are considered epithelial cells and fibroblasts are differentiated from mesenchymal cells, we hypothesized that these different origins lead to a variance of radiosensitivity between NPC cells and normal fibroblasts.
Moreover, GnT-V also targets other cellular molecules that affect tumor occurrence and development. The accumulation of β-1,6 branches on the PTPRT (receptor protein tyrosine phosphatase rho) impairs its catalytic activity, enhancing cell migration . In MCF-7 breast cancer cells, receptor-like protein tyrosine phosphatase alpha (PTPα) is a substrate of GnT-V, and the β-1,6 branches on PTPα enhance cytomembrane assembly, promoting focal adhesion formation and maturation (Xiao et al. 2017) . In colon cancer cells, the Wnt receptor FZD-7 is modified by GnT-V, and the resulting alteration of the β-1,6 branches on FZD-7 affects Wnt/β catenin signaling and tumor progression . In A549 human lung cancer cells, GnT-V restrains the epithelial-tomesenchymal transition (EMT) process by suppressing TGF-β/Smad signaling, and overexpression of GnT-V and β-1,6 branches impairs TGF-β-induced EMT, migration and invasion . Therefore, we hypothesized that the sensitivity of NPC cells is not definitively caused by a lack of branching on the EGFR. Other substrates of GnT-V might also contribute to radiosensitivity, but this hypothesis requires further studies.
In addition, different levels of the cell-surface EGFR among cells are relevant to sensitivity to cetuximab or radiation. Conflicting evidence regarding cetuximab sensitivity has been obtained. Among four NPC cell lines, HK1 (high EGFR expression) and HONE-1 (moderate EGFR expression) significantly react to cetuximab, whereas CNE-2 (moderate EGFR expression) and C666-1 (insufficient EGFR expression) did not show distinct reactions to cetuximab. Therefore, cetuximab shows selective activity in NPC cells with moderate to high EGFR protein expression (Sung et al. 2005) . Another study demonstrated that cetuximab failed to show any significant antitumour activity in cells with various EGFR expression levels, including HT29, HCT116, LOVO, Colo205, LX-1, HCC70 and N87 (Wild et al. 2006) . With respect to sensitivity to radiation, there are conflicting views regarding whether the EGFR levels are closely related to the radiotherapy response. One study investigated the expression of EGFR in 12 squamous carcinoma cell lines and demonstrated a satisfactory correlation between EGFR expression and radiosensitivity (Kasten-Pisula et al. 2011) . Another study investigated four human colon cancer cell lines (CaCo-2, HCT-8, LoVo and WiDr) and revealed an absence of correlations between the EGFR expression level and radiosensitivity (Shin et al. 2010 ).
As noted above, GnT-V, cetuximab and irradiation affected the radiosensitivity of NPC cells though β-1,6-linked branches on the EGFR, which could be one possible mechanism. However, it remains unknown whether alteration of β-1,6-linked branches would influence signals downstream of the EGFR. It has been verified that activation of the EGFR modifies the resistance of tumors to radiotherapy, and the inhibition of EGFR signaling pathways, particularly the PI3K/Akt pathway, improves the effectiveness of head and neck cancers to radiotherapy (Nijkamp et al. 2013) . Ionizing radiation induces autophosphorylation of the EGFR intracellular domains to mimic the ligand-receptor interaction, which subsequently activates downstream effectors and induces inhibition of cell survival and apoptosis (Perri et al. 2015) . PI3K/Akt signaling is a key cytoprotective response downstream of the EGFR family receptors and mediates radioresistance (Nijkamp et al. 2013) . Hyperactive PI3K/Akt, which is induced by radiation, inhibits apoptosis and activates the DNA-repair mechanism (Perri et al. 2015) . It has been reported that inhibition of N-linked glycosylation radiosensitizes tumor cells and reduces Akt phosphorylation in the U251 glioma cell line and BXPC3 pancreatic adenocarcinoma cell line (Contessa et al. 2008) . However, the correspondence of the PI3K/Akt signaling pathway and N-glycans with radiotherapy in NPC cells is currently not well understood. Our study revealed that cells that are more resistant to radiation presented higher expression levels of phospho-Akt and phospho-PI3K, whereas the more sensitive cells (GnT-V down-regulation in combination with cetuximab) showed lower expression. Therefore, we hypothesized that the combination of GnT-V down-regulation with cetuximab contributes to the phosphorylation of PI3K/AKT signaling. However, in U251 and BXPC3 cells, Akt phosphorylation is not blocked by cetuximab (Contessa et al. 2008) . The question of whether cetuximab participates in the PI3K/AKT signal pathway in radiotherapy remains to be explored.
In summary, we demonstrated that the combination of GnT-V down-regulation with cetuximab is likely related to radiosensitivity in NPC cells, and the underlying mechanism might be associated with alteration of the β-1,6-linked branches on the EGFR. These results suggest that GnT-V or its β-1,6-linked branches could be a promising target of therapeutic strategies. Furthermore, because NPC cells with low GnT-V expression benefit from radiotherapy with cetuximab, GnT-V could be regarded as a biomarker when assessing whether cetuximab should be used in radiotherapy.
Materials and methods

Cell culture and lentivirus transfection
The human NPC cell lines CNE1, CNE2 and HNE1 were purchased from Shanghai Cell Bank of Chinese Academy of Sciences (Shanghai, China). All of the cells were maintained in RPMI1640 medium (Gibco, USA) with 10% fetal bovine serum, penicillin and streptomycin at 37°C in a 5% CO 2 incubator.
The CNE1 and CNE2 cell lines were seeded in a 24-well plate at a density of 5 × 10 4 and transfected with the recombinant lentivirus LV3(H1/GFP&Puro)-has-GnT-V2224 (5′-CTCCTTTGACCCTAA GAAT-3′), LV3(H1/GFP&Puro)-has-GnT-V1564 (5′-GGAAGTGC ATGCAACTGTTTA-3′) and LV3(H1/GFP&Puro)-has-GnT-V NC (5′-TTCTCCGAACGTGTCACGTTTC-3′) to down-regulate GnT-V according to the manufacturer's instructions (Gene-Pharma, China). The transfected cells showing stable expression of GnT-V shRNA and control shRNA were maintained under puromycin (1 μg/mL), and these were denoted CNE1-NC, CNE1-1564, CNE1-2224 and CNE2-NC, CNE2-1564 and CNE2-2224. Gene expression was confirmed by both Western blot and RT-PCR assays, which were performed 3 days after transfection.
Drug preparation
Cetuximab (C225, Merck KGaA, Darmstadt, Germany) was administered as an infusion at a concentration of 5 mg/mL diluted with PBS (in vitro experiments) or normal saline (in vivo experiments). In vitro experiments with radiation and final cetuximab dilutions equal to one-fifth of the IC 50 were performed, and in vivo experiments All of the cells from the different groups were exposed to 6-Gy radiation prior to lysis. The lysate was measured using BCA kits, and similar levels of protein were analysed by SDS-PAGE to detect the expression of total Akt, p-Akt and p-PI3K. GAPDH was used as a control. This figure is available in black and white in print and in color at Glycobiology online.
using xenografts model established with a concentration of 50 mg/kg. Swainsonine (Sigma-Aldrich, St. Louis, MO) was diluted with ultrapure water to obtain a stock solution with a concentration of 1 mg/mL. The concentrations used in the in vitro and in vivo experiments were 1 μg/mL and 1 mg/kg, respectively.
RNA extraction and RT-PCR analysis
Total RNAs extracted from CNE1, CNE2 and HNE1 were obtained using the TRIzol reagent (TaKaRa Biotechnology, Dalian, China) according to the manufacturer's recommended protocol. The total RNA was reverse transcribed to cDNA using a commercial kit according to the manufacturer's instructions (TaKaRa, Dalian, China). The mRNA expression level was assessed using an SYBR PrimeScript RT-PCR kit (TaKaRa) with the following temperature program: 40 cycles of 30 s at 95°C, 5 s at 95°C and 30 s at 60°C followed by 15 s at 95°C, 45 s at 55°C and 15 s at 95°C. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the endogenous standard. The mRNA level of the samples was normalized to that of the endogenous standard and analysed using the 2 −ΔΔt method. The primer sequences used in the experiments are listed in Table I .
Western blot analysis
The cells from the different groups were lysed, and the protein content was measured using a BCA kit according to the manufacturer's recommended protocol. Cell lysates containing equal levels of protein were then separated by SDS-PAGE and then transferred to a polyvinylidene difluoride membrane (Millipore, MA, USA). After blocking with 5% bovine serum albumin, the membrane was treated overnight at 4°C with an appropriate specific antibody. The membrane was then stained with the appropriate secondary antibodies. The immunoreactive bands were visualized using an enhanced chemiluminescent (ECL) detection reagent (Millipore). The relative expression was normalized to that of GAPDH. The primary antibodies used in this study include antibodies against GnT-V (Abcam, London, UK), EGFR (Cell Signaling Technology, Danvers, MA), Akt (Cell Signaling Technology, USA), P-Akt (Bioworld, MN, USA), P-PI3K (Bioworld) and GAPDH (Bioworld).
Lectin blot analysis
The expression of β-1,6 branches was detected by lectin blot analysis with biotinylated PHA-L. The different groups of cells were exposed to 6-Gy radiation, harvested and lysed. The proteins extracted from the cells were electrophoresed by 8% SDS-PAGE using the protocol used for the Western blot analysis. After blocking with 5% bovine serum albumin in PBS containing 0.5% (w/v) Tween 20, the PVDF membrane was incubated with 10 μg/mL biotinylated L-PHA (Vector Laboratories, Burlingame, CA) for 2 h at room temperature. After staining with avidin-HRP, the bands of the PVEF membrane were detected by enhanced chemiluminescent (ECL). GAPDH was used as the standard.
PHA-L precipitation
All cells from the different groups were exposed to 6-Gy radiation prior to lysis. For lectin precipitation of the EGFR, the cell lysate (600 μg) in RIPA buffer was added to 60 μL of agarose-bound PHA-L lectin (Vector Laboratories, Burlingame, CA), and the resulting mixture was incubated overnight at 4°C under agitation. After the agarose beads were collected by centrifugation (5 s in a microcentrifuge at 14,000 rpm), the supernatants were discarded, and the beads were washed three times with ice-cold PBS. The beads were boiled with 2x SDS-PAGE protein buffer at 100°C for 5 min. After SDS-PAGE and membrane transfer, N-linked β-1,6-branching on the EGFR was detected using an antibody against EGFR.
Cell proliferation assay (CCK-8)
Different groups of cells were seeded in 96-well plates at a density of 2000 cells/well for 24 h and then exposed to 6-Gy irradiation. Twenty hours later, 10 μL of Cell Counting Kit-8 solution (Dojindo, Kuamoto, Japan) and 100 μL of RPMI-1640 plus 10% FBS were added to each well. After incubation for 120 min, the absorbance of the plates at 450 nm was measured to calculate the relative number of viable cells: growth rate (%) = (OD 450 at x h − OD 450 blank at 0 h) / (OD 450 at 0 h − OD 450 blank at 0 h).
Colony formation assay
Three hundred cells from the different groups were seeded in sixwell plates, exposed to various doses of radiation (0, 2, 4, 6 and 8 Gy) (Clinac 2300C/D, Varian, USA), and then incubated for 14 days. The colonies were then washed with PBS, fixed with 4% paraformaldehyde, stained with 10% crystal violet and counted. The colony formation rate and survival fraction were calculated as follows: colony formation rate = number of colonies at 0 Gy / number of cells seeded at 0 Gy and survival fraction (SF) = number of colonies at x Gy/(number of cells seeded at x Gy × colony formation rate). The SER was used to evaluate the increased sensitivity: SER = SF at 6 Gy prior to suppression of GnT-V/SF at 6 Gy after GnT-V suppression combined with cetuximab (Wei et al. 2011 ).
Wound healing assay
The cells of the different groups were exposed to 6-Gy radiation, seeded in six-well plates and grown to a monolayer. The wound areas were scraped using 200-μL plastic tips. PBS was used to gently wash the cell monolayer. At the indicated times (0, 24, 48 and 72 h for CNE1 cells and 0, 24 and 48 h for CNE2 cells), the wound areas were photographed, and the wound healing rate was calculated: healing rate (%) = (width of wound at 0 h − width of wound at x h) / width of wound at 0 h.
Flow cytometry assay
The cells from the different groups were harvested after 24 h of radiation with 6 Gy, washed with PBS and resuspended in binding buffer Table I . Primer sequences Name Forward primer (5′-3′) Reverse primer (5′-3′)
GnT-V GAGCAGATCCTGGACCTCAG GCTGTCATGACTCCAGCGTA EGFR ACTTCAATGGGCTCTTCCAA ACTTGTGGCTTGTGCTCCTT GAPDH GCACCGTCAAGGCTGAGAAC TGGTGAAGACGCCAGTGGA containing 7-AAD (BD Pharmingen, Santiago, CA) for 10 min. After the addition of Annexin V-PE, the degree of cell apoptosis was analysed using a flow cytometer (BD Biosciences, Oxford, United Kingdom).
Immunohistochemistry staining
Murine tumor tissues were deparaffinized and rehydrated. After blocking with 7% bovine serum albumin, the tissue sections were incubated with primary antibodies specific to EGFR (1:50, Cell Signaling Technology) and PHA-L (1:100, Vector Laboratories) at 4°C overnight. After three washes with PBS (Gibco, NY, USA), the tissue sections were incubated with horseradish peroxidase-labeled secondary antibodies (1:2000, ZSGB-BIO, Beijing, China) according to the manufacturer's instructions. Brown-yellow granules in the cytoplasm were considered to indicate positive staining for PHA-L, and the negative controls were incubated with PBS in place of the primary antibodies. The expression levels of PHA-L were classified as follows: "PHA-L negative" if the sum equalled 0, "PHA-L weak" if the sum equalled 1 (+), "PHA-L moderate" if the sum equalled 2-3 (++) and "PHA-L high" if the sum equalled 4-5 (+++) ). All of the samples were evaluated by two pathologists who were blinded to the clinical diagnosis.
In vivo tumorigenicity assay and fractional radiation
Male nude mice (4-6 weeks of age, 12-18 g) were purchased from the animal facility of Sun Yat-Sen University in Guangzhou, China. All animal experiments were approved by the Animal Ethics Committee of Sun Yat-Sen University. The stably transfected cells (6 × 10 6 ) were harvested, resuspended in 200 μL of PBS and subcutaneously injected into the left side of the recipient mice. Treatment was initiated once the tumors reached a volume of~100 mm 3 (Feng et al. 2007 ). Cetuximab (Merck KGaA, Darmstadt, Germany) was administered at a dose of 50 mg/kg, and swainsonine (Sigma-Aldrich) was administered at a dose of 1 mg/kg via i.p. injection 6 h prior to radiation on days 1, 3 and 5. Radiation therapy was administered as 2-Gy fractions on days 1-5. The tumor dimensions were measured twice weekly, and the volume was calculated according to the following equation:
where L and W are the longer and shorter dimensions of the tumor, respectively.
Statistical analysis
The data were evaluated with SPSS19.0 software and are reported as the means ± SD. Statistical analyses among the groups were performed through multiple classification ANOVA or χ 2 -test. All of the tests were two-sided, and P < 0.05 was considered to indicate a significant difference. 
